EAM Investors’s ANI Pharmaceuticals ANIP Stock Holding History

EAM Investors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,641	Closed	-$1.49M	–	242
2023 Q3	$1.49M	Buy	+25,641	New	+$1.48M	0.29%	162
2019 Q3	–	Sell	-3,287	Closed	-$270K	–	236
2019 Q2	$270K	Buy	+3,287	New	+$234K	0.07%	242
2016 Q4	–	Sell	-15,947	Closed	-$1.06M	–	314
2016 Q3	$1.06M	Sell	15,947 -2,082	-12%	-$130K	0.14%	244
2016 Q2	$1.01M	Buy	+18,029	New	+$876K	0.15%	246
2015 Q2	–	Sell	-13,682	Closed	-$856K	–	319
2015 Q1	$856K	Sell	13,682 -51,259	-79%	-$3.12M	0.1%	316
2014 Q4	$3.66M	Buy	+64,941	New	+$2.86M	0.51%	44
2014 Q3	–	Sell	-87,883	Closed	-$3.03M	–	314
2014 Q2	$3.03M	Sell	87,883 -17,117	-16%	-$537K	0.57%	18
2014 Q1	$3.29M	Buy	+105,000	New	+$2.79M	0.59%	21

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors's ANIP Position: Q4 2023 in Review

EAM Investors sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 25,641 shares — an estimated $1.49M sold.

EAM Investors first reported a position in ANIP in Q1 2014 and held it in 8 quarters. The position peaked at $3.66M in Q4 2014. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

EAM Investors reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
EAM Investors sold 25,641 ANI Pharmaceuticals shares in Q4 2023, an estimated $1.49M.
EAM Investors first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 8 quarters.
EAM Investors's ANI Pharmaceuticals position peaked at $3.66M in Q4 2014.
181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on EAM Investors's 13F filing for Q4 2023, filed 14 Feb 2024.